In today’s session Pfizer Inc. (PFE) recorded an unusually high (1,338) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the February, 2017 put, expecting serious PFE decrease. With 1,338 contracts traded and 26044 open interest for the Feb, 17 contract, it seems this is a quite bearish bet. The option with symbol: PFE170217P00030000 closed last at: $1.69 or 31% up. About 21,706 shares traded hands. Pfizer Inc. (NYSE:PFE) has declined 4.34% since April 5, 2016 and is downtrending. It has underperformed by 6.29% the S&P500.
Pfizer Inc. (NYSE:PFE) Ratings Coverage
Out of 18 analysts covering Pfizer (NYSE:PFE), 7 rate it a “Buy”, 0 “Sell”, while 11 “Hold”. This means 39% are positive. $51 is the highest target while $34 is the lowest. The $39.29 average target is 29.80% above today’s ($30.27) stock price. Pfizer has been the topic of 38 analyst reports since July 29, 2015 according to StockzIntelligence Inc. As per Thursday, April 7, the company rating was reinitiated by JP Morgan. On Friday, October 2 the stock rating was upgraded by Morgan Stanley to “Overweight”. The stock of Pfizer Inc. (NYSE:PFE) has “Hold” rating given on Wednesday, April 6 by Societe Generale. The rating was maintained by S&P Research with “Hold” on Wednesday, October 28. As per Tuesday, September 13, the company rating was maintained by Jefferies. The stock of Pfizer Inc. (NYSE:PFE) has “Overweight” rating given on Saturday, September 5 by Piper Jaffray. The stock has “Buy” rating given by Jefferies on Thursday, August 4. The firm has “Outperform” rating by Cowen & Co given on Tuesday, October 20. The firm has “Hold” rating given on Wednesday, November 2 by Argus Research. Argus Research maintained it with “Buy” rating and $46 target price in Tuesday, November 3 report.
According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment decreased to 1.03 in Q2 2016. Its down 0.21, from 1.24 in 2016Q1. The ratio fall, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
Princeton Alpha Mgmt Lp reported 42,776 shares or 0.27% of all its holdings. Gamco Et Al owns 517,941 shares or 0.12% of their US portfolio. Becker Management Inc holds 1.61 million shares or 2.31% of its portfolio. Spinnaker has 83,697 shares for 0.41% of their US portfolio. Jfs Wealth Advisors Limited Com holds 53,457 shares or 0.52% of its portfolio. Forte Capital Limited Liability Company Adv last reported 8,789 shares in the company. Wade G W And Incorporated holds 0.33% or 55,358 shares in its portfolio. Waters Parkerson And Co Lc accumulated 218,895 shares or 0.83% of the stock. Rafferty Asset Mgmt Ltd Liability owns 119,125 shares or 0.28% of their US portfolio. Bokf Na accumulated 0.55% or 439,727 shares. Pensionfund Dsm Netherlands holds 291,300 shares or 1.37% of its portfolio. Rockland Tru holds 126,599 shares or 0.67% of its portfolio. Paragon Capital Mgmt Limited Liability Company holds 0.09% or 7,479 shares in its portfolio. Brandes Prns Limited Partnership last reported 2.81% of its portfolio in the stock. Keating Inv Counselors holds 0.38% or 22,187 shares in its portfolio.
Insider Transactions: Since May 9, 2016, the stock had 0 buys, and 2 insider sales for $6.37 million net activity. Another trade for 29,600 shares valued at $1.00 million was made by HILL CHARLES H on Monday, May 9. $157,450 worth of Pfizer Inc. (NYSE:PFE) was sold by OLSON LAURIE J on Wednesday, May 11. DAMELIO FRANK A had sold 192,000 shares worth $6.46 million on Tuesday, May 10. YOUNG JOHN D sold $1.40 million worth of Pfizer Inc. (NYSE:PFE) on Tuesday, May 10. READ IAN C sold $9.30M worth of Pfizer Inc. (NYSE:PFE) on Monday, May 9. Shares for $2.92M were sold by CANGIALOSI LORETTA V. $302,063 worth of Pfizer Inc. (NYSE:PFE) was sold by MADDALUNA ANTHONY J.
Pfizer Inc. is a research-based global biopharmaceutical company. The company has a market cap of $181.01 billion. The Firm is engaged in discovering, developing and manufacturing of healthcare products. It has a 30.21 P/E ratio. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
PFE Company Profile
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.
More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Bloomberg.com which released: “Pfizer Ends Cholesterol Drug Trials as Earnings Fall Short” on November 01, 2016, also Investorplace.com with their article: “Monday’s Vital Data: Apple Inc. (AAPL), Facebook Inc (FB) and Pfizer Inc. (PFE)” published on November 07, 2016, Forbes.com published: “Ex-Dividend Reminder: Pfizer, ResMed and EverBank Financial” on November 04, 2016. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Forbes.com and their article: “Pfizer Becomes Oversold” published on October 17, 2016 as well as Forbes.com‘s news article titled: “Pfizer Divests Hospira Infusion Systems To ICU, Retaining An Interest In The …” with publication date: October 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.